Skip to main content
. 2021 Mar 1;113(6):1482–1489. doi: 10.1093/ajcn/nqaa440

FIGURE 3.

FIGURE 3

Multivariable-adjusted 10-y cumulative incidence of all-cause death by developing sarcopenia during follow-up among patients without sarcopenia at baseline (A); developing myosteatosis at follow-up among patients without myosteatosis at baseline (B); resolution of sarcopenia at follow-up among patients with sarcopenia at baseline (C); and resolution of myosteatosis at follow-up among patients with myosteatosis at baseline (D). Among all patients, the development of incident sarcopenia (HR: 1.40; 95% CI: 1.02, 1.91) and of myosteatosis (HR: 1.41; 95% CI: 1.05, 1.90) were associated with a higher risk of death independently of change in body weight. The resolution of prevalent sarcopenia (HR: 0.86; 95% CI: 0.61, 1.21) and of myosteatosis (HR: 0.74; 95% CI: 0.51, 1.07) were not associated with the risk of death independently of change in body weight. Solid lines represent point estimates and shaded areas represent the corresponding 95% CIs estimated from a flexible parametric proportional hazards survival model.